Endpoint definition
↥| Name | KELA_DIAB_INSUL |
|---|---|
| Long name | Diabetes, insuline treatment (Kela reimbursement) |
| KELA reimboursements codes | 103 |
| First defined in version | DF2 |
| Name | KELA_DIAB_INSUL |
|---|---|
| Long name | Diabetes, insuline treatment (Kela reimbursement) |
| KELA reimboursements codes | 103 |
| First defined in version | DF2 |
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 29071 | 12996 | 16075 |
| Unadjusted prevalence (%) | 13.40 | 10.58 | 17.07 |
| Mean age at first event (years) | 53.75 | 53.20 | 54.20 |
| Case fatality at 5-years (%) | 2.84 | 1.85 | 3.65 |
| All | Female | Male | |
|---|---|---|---|
| Median nb. of events per indiv. | 1.0 | 1.0 | 1.0 |
| Recurrence at 6 months (%) | 0.02 | 0.02 | 0.02 |
before Diabetes, insuline treatment (Kela reimbursement)
after Diabetes, insuline treatment (Kela reimbursement)
Loading survival analyses plot…
Loading survival analyses table…